Issue 93

The Mental Health of Children and Adolescents

The Kids Are Not Alright

The World Health Organization recently released its mental health report, which analysed the scale of the mental health crisis and set forth actionable steps for governments worldwide.

Worryingly, it also outlined a decline in the mental health of children and adolescents. It was revealed 14% of adolescents are currently living with a mental disorder and, as many do not respond to conventional treatments, suicide is the fourth leading cause of death in 15–29-year-olds.

Many mental illnesses are rooted in childhood, with onset during these critical years. By recognising the decline in the mental health of children today, healthcare providers can better prepare for the challenges faced tomorrow.

READ MORE

A NEED FOR 100,000 PSYCHEDELIC-ASSISTED THERAPISTS

MAPS’ Founder Rick Doblin commented on therapist numbers in psychedelic healthcare.

Read More

NHS BOOSTS CHILDREN'S MENTAL HEALTH WORKFORCE BY 40%

Demand for NHS services surged in the pandemic and 22,000 roles remain unfilled.

Read More

BUSINESS AND INVESTMENT

COMPASS releases Q2 2022 financial results.

Common myths in mental health.

Braxia Scientific to acquire KetaMD.

Can Europe withstand a winter recession?

COMPASS sued for appropriation of trade secrets.

MindMed directors approve reverse share split.

SCIENCE AND RESEARCH

Petition – reschedule psilocybin in the UK.

Double-action mechanism makes ketamine less addictive.

The Psychedelics as Medicine Report provides market insights from industry experts.

With over 60,000 downloads, the flagship publication contains proprietary data for regulators, researchers and investors to make informed decisions.

Previous partners include atai Life Sciences, COMPASS Pathways, Cybin and Filament Health.

To be included in the fourth edition and to discuss future events, please contact grace@psych.global

CONTACT FORM

REGULATION AND LEGISLATION

Impact of psilocybin regulation in Canada.

Oregon counties to vote on psilocybin framework.

Colorado’s second decriminalisation measure falls short.

The decriminalisation of psychedelic medicines in California.